文献速递心脑血管急症

秋水仙碱用于慢性冠心病患者

Colchicine in Patients with Chronic Coronary Disease.
PubMed 文献 · N Engl J Med · 2020-08-31
一句话结论慢性冠心病患者每日秋水仙碱0.5 mg可显著降低心血管复合终点事件风险(HR 0.69)。

该随机双盲对照试验纳入5522例慢性冠心病患者,随机分入秋水仙碱0.5 mg每日一次组或安慰剂组,中位随访28.6个月。主要复合终点(心血管死亡、自发性心肌梗死、缺血性卒中或缺血驱动的冠状动脉血运重建)在秋水仙碱组发生187例(6.8%),安慰剂组264例(9.6%),HR 0.69(95%CI 0.57–0.83,P<0.001)。关键次要终点(心血管死亡、自发性心肌梗死或缺血性卒中)HR 0.72(95%CI 0.57–0.92,P=0.007)。非心血管原因死亡发生率秋水仙碱组高于安慰剂组(每100人年0.7 vs 0.5,HR 1.51,95%CI 0.99–2.31)。

要点

  • 慢性冠心病患者每日秋水仙碱0.5 mg,主要复合终点事件发生率6.8% vs 安慰剂9.6%(HR 0.69,95%CI 0.57–0.83,P<0.001)。
  • 关键次要终点(心血管死亡、自发性心肌梗死或缺血性卒中)发生率4.2% vs 5.7%(HR 0.72,95%CI 0.57–0.92,P=0.007)。
  • 非心血管原因死亡发生率秋水仙碱组高于安慰剂组(每100人年0.7 vs 0.5,HR 1.51,95%CI 0.99–2.31)。
  • 自发性心肌梗死或缺血驱动的冠状动脉血运重建复合终点、心血管死亡或自发性心肌梗死复合终点、缺血驱动的冠状动脉血运重建、自发性心肌梗死发生率均秋水仙碱组显著低于安慰剂组。
  • 中位随访28.6个月,慢性冠心病患者每日秋水仙碱0.5 mg口服,主要终点事件每100人年2.5 vs 3.6。

适用人群与场景

  • 慢性冠心病患者,随机接受秋水仙碱0.5 mg每日一次或安慰剂。

处置流程与药物剂量

  • 秋水仙碱0.5 mg每日一次口服,与安慰剂对照,用于慢性冠心病患者。

研究设计与关键结果

  • 随机、对照、双盲试验,共5522例患者随机,秋水仙碱组2762例,安慰剂组2760例,中位随访28.6个月。
  • 主要复合终点(心血管死亡、自发性心肌梗死、缺血性卒中或缺血驱动的冠状动脉血运重建)秋水仙碱组187例(6.8%)vs 安慰剂组264例(9.6%),每100人年2.5 vs 3.6,HR 0.69(95%CI 0.57–0.83),P<0.001。
  • 关键次要复合终点(心血管死亡、自发性心肌梗死或缺血性卒中)秋水仙碱组115例(4.2%)vs 安慰剂组157例(5.7%),每100人年1.5 vs 2.1,HR 0.72(95%CI 0.57–0.92),P=0.007。
  • 非心血管原因死亡发生率秋水仙碱组高于安慰剂组(每100人年0.7 vs 0.5,HR 1.51,95%CI 0.99–2.31)。
  • 自发性心肌梗死或缺血驱动的冠状动脉血运重建复合终点、心血管死亡或自发性心肌梗死复合终点、缺血驱动的冠状动脉血运重建、自发性心肌梗死发生率均秋水仙碱组显著低于安慰剂组。

证据类型、等级与局限

  • 随机、对照、双盲试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 慢性冠心病患者每日秋水仙碱0.5 mg口服可降低主要心血管复合终点事件风险,但非心血管原因死亡发生率在秋水仙碱组数值上更高(HR 1.51,95%CI 0.99–2.31)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited.

METHODS: In a randomized, controlled, double-blind trial, we assigned patients with chronic coronary disease to receive 0.5 mg of colchicine once daily or matching placebo. The primary end point was a composite of cardiovascular death, spontaneous (nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. The key secondary end point was a composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke.

RESULTS: A total of 5522 patients underwent randomization; 2762 were assigned to the colchicine group and 2760 to the placebo group. The median duration of follow-up was 28.6 months. A primary end-point event occurred in 187 patients (6.8%) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). A key secondary end-point event occurred in 115 patients (4.2%) in the colchicine group and in 157 patients (5.7%) in the placebo group (incidence, 1.5 vs. 2.1 events per 100 person-years; hazard ratio, 0.72; 95% CI, 0.57 to 0.92; P = 0.007). The incidence rates of spontaneous myocardial infarction or ischemia-driven coronary revascularization (composite end point), cardiovascular death or spontaneous myocardial infarction (composite end point), ischemia-driven coronary revascularization, and spontaneous myocardial infarction were also significantly lower with colchicine than with placebo. The incidence of death from noncardiovascular causes was higher in the colchicine group than in the placebo group (incidence, 0.7 vs. 0.5 events per 100 person-years; hazard ratio, 1.51; 95% CI, 0.99 to 2.31).

CONCLUSIONS: In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo. (Funded by the National Health Medical Research Council of Australia and others; LoDoCo2 Australian New Zealand Clinical Trials Registry number, ACTRN12614000093684.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020. PMID: 32865380. doi:10.1056/NEJMoa2021372

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。